BioNTech:HC Wainwright Downgrades to Buy, PT Reduced to $136 from $138
ByAinvest
Thursday, Aug 14, 2025 11:53 am ET1min read
BNTX--
The downgrade follows BioNTech's partnership with the Peter MacCallum Cancer Centre to establish a clinical trial platform in Victoria, aimed at improving access to investigational cancer treatments [1]. The platform, which includes key delivery partners like Austin Health, Alfred Health, and Monash Health, is designed to streamline clinical trials and expedite the development of innovative therapies.
Despite the downgrade, BioNTech reported strong quarterly revenue of $306.46 million, exceeding analyst expectations, but it also reported a loss of ($1.60) EPS, falling short of the anticipated ($1.41) [2]. This indicates ongoing volatility in the company's earnings performance.
The downgrade by HC Wainwright comes amidst a mixed picture of institutional investor sentiment. TD Asset Management Inc significantly reduced its stake in BioNTech by 74%, but several other institutional investors increased their holdings, with increases ranging from 7.1% to 34.2% [2]. The company's stock has seen a 241,226 shares traded on Friday, reaching $112.09, with a market cap of $26.95 billion and a PE ratio of -70.11 [2].
Analysts have a mixed sentiment towards BioNTech, with five analysts rating the stock with a hold rating and thirteen giving a buy rating, resulting in an average rating of "Moderate Buy" and an average price target of $135.91 [2].
References:
[1] https://www.invest.vic.gov.au/news-and-events/news/2025/august/new-biontech-clinical-trail-platform-to-improve-clinical-trial-access-for-cancer-patients
[2] https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-trims-stake-in-biontech-se-sponsored-adr-nasdaqbntx-2025-08-05/
BioNTech:HC Wainwright Downgrades to Buy, PT Reduced to $136 from $138
Victoria, Australia, July 2, 2025 — BioNTech SE, a leading biotechnology company, has seen its stock rating downgraded by HC Wainwright from a "buy" to a "buy" with a reduced price target of $136, down from $138 [1]. The downgrade comes amidst significant developments in the company's clinical trial platform and recent financial performance.The downgrade follows BioNTech's partnership with the Peter MacCallum Cancer Centre to establish a clinical trial platform in Victoria, aimed at improving access to investigational cancer treatments [1]. The platform, which includes key delivery partners like Austin Health, Alfred Health, and Monash Health, is designed to streamline clinical trials and expedite the development of innovative therapies.
Despite the downgrade, BioNTech reported strong quarterly revenue of $306.46 million, exceeding analyst expectations, but it also reported a loss of ($1.60) EPS, falling short of the anticipated ($1.41) [2]. This indicates ongoing volatility in the company's earnings performance.
The downgrade by HC Wainwright comes amidst a mixed picture of institutional investor sentiment. TD Asset Management Inc significantly reduced its stake in BioNTech by 74%, but several other institutional investors increased their holdings, with increases ranging from 7.1% to 34.2% [2]. The company's stock has seen a 241,226 shares traded on Friday, reaching $112.09, with a market cap of $26.95 billion and a PE ratio of -70.11 [2].
Analysts have a mixed sentiment towards BioNTech, with five analysts rating the stock with a hold rating and thirteen giving a buy rating, resulting in an average rating of "Moderate Buy" and an average price target of $135.91 [2].
References:
[1] https://www.invest.vic.gov.au/news-and-events/news/2025/august/new-biontech-clinical-trail-platform-to-improve-clinical-trial-access-for-cancer-patients
[2] https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-trims-stake-in-biontech-se-sponsored-adr-nasdaqbntx-2025-08-05/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet